Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection

Vaccine

Volumn 32, Issue 22, 2014, Pages 2546-2552

  Esposito, Susanna ^a   Marchisio, Paola ^a   Prada, Elisabetta ^a   Daleno, Cristina ^a   Porretti, Laura ^b   Carsetti, Rita ^c   Bosco, Annalisa ^a   Ierardi, Valentina ^a   Scala, Alessia ^a   Principi, Nicola ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Bacterial lysate; Children; Influenza; Influenza vaccine; OM 85 BV; Recurrent respiratory tract infection

Indexed keywords

BACTERIUM LYSATE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INFLUENZA VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; INFLUENZA VACCINATION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; MALE; MEMORY CELL; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; SEROCONVERSION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SKIN INDURATION; SOMNOLENCE; VOMITING;

BACTERIAL LYSATE; CHILDREN; INFLUENZA; INFLUENZA VACCINE; OM-85 BV; RECURRENT RESPIRATORY TRACT INFECTION;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CELL EXTRACTS; CHILD, PRESCHOOL; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGIC MEMORY; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PROSPECTIVE STUDIES; RECURRENCE; RESPIRATORY TRACT INFECTIONS; SINGLE-BLIND METHOD; VACCINES, INACTIVATED;

EID: 84898546522     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.03.055     Document Type: Article

References (32)

1. Principi N., Esposito S., Cavagna R., Bosis S., Droghetti R., Faelli N., et al. Recurrent respiratory tract infections in pediatric age: a population-based survey of the therapeutic role of macrolides. J Chemother 2003, 15:53-59.
2. Esposito S., Musio A. Immunostimulants and prevention of recurrent respiratory tract infections. J Biol Regul Homeost Agents 2013, 27:627-636.
3. Cazzola M., Anapurapu S., Page C.P. Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: a meta-analysis. Pulm Pharmacol Ther 2012, 25:62-68.
4. Schaad U.B. OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review. World J Pediatr 2010, 6:5-12.
5. Esposito S., Marchisio P., Cavagna R., Gironi S., Bosis S., Lambertini L., et al. Effectiveness of influenza vaccination of children with recurrent respiratory tract infections in reducing respiratory-related morbidity within the households. Vaccine 2003, 21:3162-3168.
6. Lanzilli G., Falchetti R., Tricarico M., Ungheri D., Fuggetta M.P. In vitro effects of an immunostimulating bacterial lysate on human lymphocyte function. Int J Immunopathol Pharmacol 2005, 18:245-254.
7. Holt P.G. Infection and the development of allergic disease. Allergy 2011, 66(Suppl. 95):13-15.
8. Bowman L.M., Holt P.G. Selective enhancement of systemic Th1 immunity in immunologically immature rats with an orally administered bacterial extract. Infect Immun 2001, 69:3719-3727.
9. Broncho-vaxom - Package leaflet. Available at:. [accessed 06.12.13]. http://www.torrinomedica.it/farmaci/schedetecniche/Broncho_Vaxom.asp.
10. Esposito S., Tagliabue C., Tagliaferri L., Semino M., Longo M.R., Principi N. Preventing influenza in younger children. Clin Microbiol Infect 2012, 18(Suppl. 5):42-49.
11. Esposito S., Montinaro V., Bosis S., Tagliabue C., Baggi E., Principi N. Recommendations for the use of influenza vaccine in pediatrics. Hum Vaccin Immunother 2012, 8:102-106.
12. Esposito S., Montinaro V., Groppali E., Tenconi R., Semino M., Principi N. Live attenuated intranasal influenza vaccine. Hum Vaccin Immunother 2012, 8:76-80.
13. MedImmune. FluMist - Highlights of prescribing information. Available at: [accessed 03.12.13]. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm294307.pdf.
14. Principi N., Esposito S. Adjuvanted influenza vaccines. Hum Vaccin Immunother 2012, 8:59-66.
15. Esposito S., Marchisio P., Ansaldi F., Bianchini S., Pacei M., Baggi E., et al. A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months. Vaccine 2010, 28:6137-6144.
16. Esposito S., Daleno C., Picciolli I., Tagliaferri L., Scala A., Prunotto G., et al. Immunogenicity and safety of intradermal influenza vaccine in children. Vaccine 2011, 29:7606-7610.
17. Ansaldi F., Bacilieri S., Durando P., Sticchi L., Valle L., Montomoli E., et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008, 26:1525-1529.
18. Setti M., Fenoglio D., Ansaldi F., Filaci G., Bacilieri S., Sticchi L., et al. Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine 2009, 27:3367-3372.
19. Tanzi E., Esposito S., Bojanin J., Amendola A., Trabattoni D., Pariani E., et al. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T cell activation in HIV-infected children receiving highly active antiretroviral therapy. J Med Virol 2006, 78:440-445.
20. European Agency for the Evaluation of Medicinal Products (EMEA) - Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonization of requirements for influenza vaccines (CPMP/BWP/214/96). London; March 1997.
21. Kanra G., Marchisio P., Feiterna-Sperling C., Gaedicke G., Lazar H., Durrer P., et al. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 2004, 23:300-306.
22. Hesselink D.A., Vaessen L.M.B., Hop W.C.J., Schoordijk W., Ijzermans J.N.M., Baan C.C., et al. The effect of renal transplantation on circulating dendritic cells. Clin Exp Immunol 2005, 140:384-393.
23. Field J., Gómez-Barreto D., Del-Río-Navarro B.E., Berber A. Use of OM-85 BV in primary prevention of acute respiratory tract infections in children in orphanages. Curr Ther Res 1998, 59:407-418.
24. Schaad U.B., Mutterlein R., Goffin H. Immunostimulation with OM-85 in children with recurrent infections of the upper respiratory tract: a double-blind, placebo-controlled multicenter study. Chest 2002, 122:2042-2049. BV-Child Study Group.
25. Del-Rio-Navarro B.E., Luis Sienra-Monge J.J., Berber A., Torres-Alcantara S., Avila-Castanon L., Gomez-Barreto D. Use of OM-85 BV in children suffering from recurrent respiratory tract infections and subnormal IgG subclass levels. Allergol Immunopathol (Madr) 2003, 31:7-13.
26. Razi C.H., Harmanci K., Abaci A., Özdemir O., Hizli S., Renda R., et al. The immunostimulant OM-85 BV prevents wheezing attacks in preschool children. J Allergy Clin Immunol 2010, 126:763-769.
27. Bitar M.A., Saade R. The role of OM-85 BV (broncho-vaxom) in preventing recurrent acute tonsillitis in children. Int J Pediatr Otorhinolaryngol 2013, 77:670-673.
28. de Haan A., Haijema B.J., Voorn P., Meijerhof T., van Roosmalen M.L., Leenhouts K. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration. Vaccine 2012, 30:4884-4891.
29. Xu M.L., Kim H.J., Choi Y.R., Kim H.J. Intake of korean red ginseng extract and saponin enhances the protection conferred by vaccination with inactivated influenza a virus. J Ginseng Res 2012, 36:396-402.
30. Zelle-Rieser C., Ramoner R., Bartsch G., Thurnher M. A clinically approved oral vaccine against pneumotropic bacteria induces the terminal maturation of CD83+ immunostimulatory dendritic cells. Immunol Lett 2001, 76:63-67.
31. Spisek R., Brazova J., Rozkova D., Zapletalova K., Sediva A., Bartunkova J. Maturation of dendritic cells by bacterial immunomodulators. Vaccine 2004, 22:2761-2768.
32. Zuccotti G.V., Mameli C., Trabattoni D., Beretta S., Biasin M., Guazzarotti L., et al. Immunomodulating activity of pidotimod in children with Down syndrome. J Biol Regul Homeost Agents 2013, 27:253-258.